english.prescrire.org > Topics > Advancing healthcare policy > Proposed recommendations on drug brand names by France's Health Products Agency maintain dangerous confusion (12/2016)
Advancing healthcare policy

Via its policy advocacy, Prescrire acts as a force for change in health policies, first and foremost in the interest of patients.

Français

The proposed recommendations on drug brand names by France's Health Products Agency: a plan that maintains dangerous name confusion (December 2016)

Prescrire urges the French Health Products Agency (ANSM) to revise its draft recommendations on drug brand names in a way that maximises patient safety, abandoning national practices of brand names and labelling consisting of a hotchpotch of terms that cause medication errors by creating confusion. The ANSM is also urged to stop legitimising the continued presence of umbrella brands on the market, given the dangers they pose for patients, by challenging their regulatory compliance. Read on...
 


Paris, 14 December 2016

 

Prescrire urges the French Health Products Agency (ANSM) to revise its draft recommendations on drug brand names in a way that maximises patient safety, abandoning national practices of brand names and labelling consisting of a hotchpotch of terms that cause medication errors by creating confusion. The ANSM is also urged to stop legitimising the continued presence of umbrella brands on the market, given the dangers they pose for patients, by challenging their regulatory compliance.
 

> Click here to download Prescrire's response (pdf, 226 Ko)
 

©Prescrire December 2016